Exparel for Reducing Narcotics After Maxillary Orthognathic Surgery

This clinical trial explores the use of Exparel, a type of liposomal bupivacaine, in patients undergoing maxillary orthognathic surgery, a jaw surgery. The primary goal is to see if Exparel can reduce the need for opioids, which are strong painkillers that can have significant side effects and addiction potential, compared to the traditional use of bupivacaine alone. The study targets 100 individuals scheduled for this type of surgery and divides them into two groups: one receiving Exparel and the other receiving standard bupivacaine. This research is important because it could lead to better pain management options and improve recovery experiences, minimizing the risks associated with opioid use. Participants in the study will receive an injection of either 133 mg of Exparel or 50 mg of bupivacaine near the incision sites at the end of their surgery. All participants will have their anesthesia managed without opioids and will stay in the hospital for one night after the procedure for observation. Over the next week, participants will keep a daily diary to record their pain levels, quality of life factors like nausea and swelling, and any medications taken. After a week, they will return to the clinic to complete a questionnaire about their experience. This helps researchers determine how effective Exparel is in managing post-surgery pain and improving recovery.